Charles Schwab
CERE

Charles Schwab’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Charles Schwab’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-522,930
Closed -$21.4M – 3644
2024
Q2 		$21.4M Sell
522,930
-142,901
-21% -$5.95M ﹤0.01% 1637
2024
Q1 		$28.1M Buy
665,831
+16,498
+3% +$693K 0.01% 1413
2023
Q4 		$27.5M Buy
649,333
+132,089
+26% +$3.8M 0.01% 1388
2023
Q3 		$11.3M Buy
517,244
+15,261
+3% +$382K ﹤0.01% 1848
2023
Q2 		$16M Buy
501,983
+15,000
+3% +$460K ﹤0.01% 1649
2023
Q1 		$11.9M Buy
486,983
+1,639
+0.3% +$48.1K ﹤0.01% 1789
2022
Q4 		$15.3M Buy
485,344
+17,558
+4% +$495K ﹤0.01% 1614
2022
Q3 		$13.2M Buy
467,786
+72,301
+18% +$2.15M ﹤0.01% 1663
2022
Q2 		$10.5M Buy
395,485
+22,924
+6% +$651K ﹤0.01% 1819
2022
Q1 		$13M Buy
372,561
+9,441
+3% +$276K ﹤0.01% 1803
2021
Q4 		$11.8M Buy
363,120
+11,312
+3% +$399K ﹤0.01% 1921
2021
Q3 		$10.4M Buy
351,808
+100,315
+40% +$2.82M ﹤0.01% 1987
2021
Q2 		$6.44M Buy
251,493
+79,823
+46% +$1.14M ﹤0.01% 2222
2021
Q1 		$2.36M Buy
171,670
+4,960
+3% +$72.6K ﹤0.01% 2616
2020
Q4 		$2.77M Buy
+166,710
New +$2.17M ﹤0.01% 2499

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Charles Schwab's CERE Position: Q3 2024 in Review

Charles Schwab sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 522,930 shares — an estimated $21.4M sold.

Charles Schwab first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $28.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Charles Schwab reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Charles Schwab sold 522,930 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $21.4M.
  • Charles Schwab first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • Charles Schwab's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $28.1M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Charles Schwab's 13F filing for Q3 2024, filed 12 Nov 2024.